Macuject

Cover Block

PUBLIC

Name	Macuject
Tagline	Cloud-based SaaS using AI for macular fluid analysis and clinical decisions in wet AMD.
Headquarters	Australia
Founded	2017 [PitchBook, 2025]
Stage	Seed
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Oceania
Growth Profile	Venture Scale
Founding Team	Dr Devinder Chauhan (clinician/ophthalmologist) [Bionics Institute]
Funding Label	Seed
Total Disclosed	$0.62M (estimated) [HealthTechAlpha]

Links

PUBLIC

• Website: https://www.macuject.com
• LinkedIn: https://au.linkedin.com/company/macuject

Executive Summary

PUBLIC Macuject is a clinician-driven SaaS platform using proprietary AI to standardize and accelerate treatment decisions for wet age-related macular degeneration (AMD), a high-stakes clinical area where suboptimal care remains common despite effective therapies [Macuject.com]. Founded in 2017 by ophthalmologist Dr Devinder Chauhan, the company has progressed from beta testing with Australian specialists to early commercial use in private clinics, with stated plans for a U.S. rollout [mivision 2021, Medium]. Its differentiation lies not just in automated fluid analysis, but in integrating those quantifications with patient history dashboards and customizable clinical decision trees, aiming to embed the platform directly into the ophthalmologist's workflow.

The executive team, assembled post-founding, brings commercialization and technical experience from adjacent sectors, with the CTO having led SOC2 and HIPAA compliance efforts [Bradley Beddoes LinkedIn, Crunchbase]. To date, the company has raised approximately $620,000 in total disclosed funding, primarily through participation in the ANDHealth+ accelerator program, and is seeking capital for product expansion and regulatory work [HealthTechAlpha, Macuject.com/blog-pages/andhealth-plus]. Over the next 12-18 months, the key milestones to watch are the completion of its decision tree for diabetic macular edema, progress toward U.S. Food and Drug Administration clearance for the web app, and the translation of early Australian clinic usage into named customer deployments and recurring revenue [mivision 2022].

Data Accuracy: YELLOW -- Core product claims are company-sourced and consistent; funding and team details have partial third-party corroboration but lack comprehensive verification.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Oceania
Growth Profile	Venture Scale
Funding	Seed (total disclosed ~$620,000)

Company Overview

PUBLIC

Macuject is a clinician-founded digital health company established in 2017 and headquartered in Australia [PitchBook, 2025][Bounce Watch]. The company was created by Dr Devinder Chauhan, an ophthalmologist, with the stated mission to address preventable blindness, beginning with wet age-related macular degeneration (AMD) [Bionics Institute]. The founding narrative is clinician-driven, focusing on translating direct experience with treatment inefficiencies into a software solution.

Key operational milestones have centered on product development and early validation. The platform entered a beta testing phase with a select group of ophthalmologists for several months as of May 2021 [mivision 2021]. By 2022, the company was participating in the ANDHealth+ accelerator program and publicly stated it was seeking capital to complete a decision-making tree for diabetic macular oedema and to pursue regulatory approval for its web app in the United States [mivision 2022][Macuject.com/blog-pages/andhealth-plus]. A compliance milestone for the platform, achieving SOC2 and HIPAA standards, was led by CTO Bradley Beddoes [Bradley Beddoes LinkedIn].

The company's commercial footprint, according to a 2023 investor blog post, includes use in private clinics in Australia with plans to roll out in the United States [Medium Verge Healthtech]. The executive team has been built out with roles including a Chief Operating Officer and a Chief Commercialisation Officer, though their tenures and specific contributions to company milestones are not detailed in public sources [Crunchbase].

Data Accuracy: YELLOW -- Core founding date and location corroborated by multiple databases; specific milestones are cited from dated trade press and company blog, but some executive team details lack independent verification.

Product and Technology

MIXED The core offering is a cloud-based SaaS platform designed to augment, not replace, the clinical workflow for ophthalmologists treating wet age-related macular degeneration. The product's differentiation lies in its clinician-driven design, which moves beyond simple scan analysis to integrate quantitative fluid measurements with patient history dashboards and customizable decision trees [Macuject.com]. This combination aims to address a specific clinical bottleneck: enabling doctors to manage more patients while making more consistent and confident treatment decisions [Medium].

The platform's primary function is the quantitative analysis of macular fluid from Optical Coherence Tomography (OCT) scans using proprietary AI. This analysis feeds into a patient dashboard that consolidates historical treatment data, and then into a clinical decision support module. The company has stated the platform is in use within private clinics in Australia and is preparing for a rollout in the United States [Medium]. As of May 2021, the product was in beta testing with a select group of ophthalmologists [mivision 2021]. A key public milestone was achieving SOC2 and HIPAA compliance, a necessary step for handling protected health information in the US market [Bradley Beddoes LinkedIn].

Publicly stated development goals include completing a decision-making tree for diabetic macular oedema and pursuing FDA approval for the web application [mivision 2022]. The technology stack is not detailed, but the cloud-based architecture and compliance achievements suggest a modern, security-focused SaaS infrastructure.

Data Accuracy: YELLOW -- Core product claims are confirmed by the company website and investor blog. Deployment and compliance claims are sourced from a single publication each.

Market Research and Opportunity

PUBLIC

The market for AI-assisted ophthalmic diagnostics is defined by a persistent clinical gap between available treatments and patient access, creating a clear wedge for software that improves clinician efficiency.

Quantitative market sizing for AI in wet AMD management is not publicly available from third-party reports. Analysts can look to analogous segments for scale. The broader AI in medical imaging market was valued at $1.2 billion in 2022 and is projected to reach $4.5 billion by 2028, according to a report cited by PitchBook [PitchBook, 2025]. Within ophthalmology specifically, the global age-related macular degeneration therapeutics market is a multi-billion dollar segment, indicating the high economic value of effective disease management where Macuject's platform aims to play a supporting role.

Demand is driven by demographic aging and the growing burden of chronic eye disease. Age-related macular degeneration is a leading cause of blindness in developed nations, with wet AMD representing the more severe, vision-threatening form. While anti-VEGF injections are a highly effective treatment, the regimen requires frequent monitoring and precise, individualized dosing decisions. This creates a significant operational strain on retina specialists, a workforce bottleneck that software can help alleviate. The tailwind for AI adoption in this space is reinforced by increasing clinician familiarity with digital tools and a broader push towards value-based care models that reward efficiency and consistent outcomes [Medium, Unknown].

Adjacent and substitute markets include the broader retinal diagnostics software ecosystem and integrated hardware-software solutions from OCT manufacturers. Companies like Heidelberg Engineering and Zeiss offer proprietary analysis software bundled with their imaging devices, which represents a competitive but also partnership-oriented channel. The regulatory environment is a key force. In the United States, Macuject has stated it is seeking FDA approval for its web app [mivision, 2022], a process that will define its commercial pathway and timeline. Success in regulated markets like the U.S. and Europe is often a prerequisite for scaling reimbursement and health system adoption.

AI Medical Imaging Market 2022 | 1200 | $M
AI Medical Imaging Market 2028 (projected) | 4500 | $M

The projected growth in the AI medical imaging market suggests a receptive and expanding environment for specialized applications, though Macuject's specific addressable segment within wet AMD workflow tools remains a fraction of this total.

Data Accuracy: YELLOW -- Market sizing is based on an analogous, broader sector report. Specific TAM for the product's niche is not confirmed.

Competitive Landscape

MIXED Macuject's competitive position is defined by a clinician-first workflow that integrates analysis and decision support, a focus that distinguishes it from pure-play imaging tools.

If the structured facts include at least one named competitor, render a markdown comparison table with header row "Company | Positioning | Stage / Funding | Notable Differentiator | Source"; put the subject in the first row plus 2-5 named competitors. If there are zero named competitors in the structured facts, OMIT the table entirely and write the competitive analysis as prose only, do NOT render a table whose only non-subject row is a placeholder.

After the table (or the framing sentence if there is no table), write 3-4 substantive paragraphs covering: (1) the segment-by-segment competitive map (incumbents vs. challengers vs. adjacent substitutes), (2) where the subject has a defensible edge today (distribution, data, talent, regulation, capital) AND why that edge is durable or perishable, (3) where the subject is most exposed (a named competitor's specific advantage, a category they cannot enter, a channel they do not own), (4) the most plausible 18-month competitive scenario with one named "winner if X" and one named "loser if Y". Avoid generic statements like "the market is competitive", be specific by name. Label MIXED. End with accuracy score.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Macuject	Cloud-based SaaS for macular fluid analysis and clinical decision trees in wet AMD.	Seed (~$0.62M) [HealthTechAlpha]	Clinician-driven workflow integrating quantitative analysis with customizable decision support.	[Macuject.com]
RetinAI	AI-powered platform for retina image analysis and data management.	Series A ($6M, 2021) [Crunchbase]	Broader focus on data management and analytics across multiple retinal diseases.	[Crunchbase]
Notal Vision	Remote patient monitoring and home-based diagnostic devices for AMD.	Late-stage private (Funded by Novartis, $50M+ raised) [Crunchbase]	Proprietary hardware (ForeseeHome) for at-home monitoring, with established FDA clearances.	[Crunchbase]
RetInSight	AI-based software for automated analysis of retinal OCT scans.	Seed (€1.5M, 2020) [Crunchbase]	Focus on fully automated, CE-marked quantification of retinal fluid and layers.	[Crunchbase]

The competitive map in ophthalmic AI is segmented by function. Incumbent diagnostic device manufacturers, like Heidelberg Engineering and Zeiss, embed basic quantification tools within their hardware, creating a high-barrier, capital-intensive channel. Challengers like RetinAI and RetInSight are pure software plays focusing on automated image analysis, often positioning as a layer on top of existing imaging systems. Adjacent substitutes include integrated electronic health record (EHR) platforms and telemedicine services, which could develop or acquire similar decision-support modules. Macuject's stated wedge is its integration of analysis with subsequent clinical decision trees, aiming to own more of the post-scan workflow than an analysis-only tool [Macuject.com].

Macuject's primary edge appears to be its founder-clinician orientation and early Australian clinic integrations. The founder, Dr. Devinder Chauhan, is a practicing ophthalmologist, which lends credibility to the platform's workflow design [Bionics Institute]. The company also reports its platform is "currently used in private clinics in Australia" [Medium Verge Healthtech]. This clinical co-design and real-world testing could create an early data feedback loop and user loyalty. However, this edge is perishable. It depends on maintaining a lead in clinician adoption within a limited geographic footprint before larger, well-funded competitors can replicate the decision-support logic or acquire similar clinical expertise.

The company is most exposed in two areas: regulatory pathways and sales channel depth. A competitor like Notal Vision has a significant advantage with its FDA-cleared hardware and established reimbursement codes for remote monitoring, a regulatory moat Macuject has yet to build for its software [Crunchbase]. Furthermore, Macuject does not own the imaging hardware channel. Its success relies on convincing clinics to adopt a third-party SaaS layer, a process that may be slower than the integrated sales motion of an OCT manufacturer launching a competing software module.

The most plausible 18-month scenario hinges on regulatory execution and partnership formation. If Macuject secures its targeted FDA approval for the web app and lands a distribution partnership with a mid-tier OCT manufacturer or a pharmaceutical company, it could become a winner in the niche of integrated wet AMD management [mivision 2022]. Conversely, if it fails to progress beyond Australian beta tests while a competitor like RetinAI expands its platform to include robust decision-support features, Macuject would be a loser in the race for clinical mindshare and risk becoming a feature rather than a platform.

Data Accuracy: YELLOW -- Competitor profiles are sourced from Crunchbase; Macuject's differentiation is based on its public materials. The competitive dynamics are inferred from these public positions.

Opportunity

PUBLIC

If Macuject can establish its AI-driven workflow as a standard of care in the management of wet AMD, it would capture a significant portion of a multi-billion dollar global treatment market that is currently underserved by consistent, quantitative analysis.

The headline opportunity is for Macuject to become the default clinical workflow platform for retinal specialists managing chronic eye diseases, beginning with wet AMD. This outcome is reachable because the company is building from a clinician-first foundation, not just an algorithm. The product integrates quantitative fluid analysis with patient dashboards and customizable decision trees, directly addressing the documented shortfall in optimal treatment delivery even in wealthy countries [Macuject.com]. Early, real-world use in Australian private clinics provides a critical proof point that the software fits into existing clinical practice, which is a more significant hurdle for adoption than algorithmic accuracy alone [Medium, Unknown]. By solving for workflow efficiency and decision confidence, Macuject positions itself as an essential operating system for the clinic, not just another diagnostic viewer.

Growth from a niche Australian tool to a category-defining platform hinges on a few concrete, named paths. The following scenarios outline plausible routes to scale.

Scenario	What happens	Catalyst	Why it's plausible
Regulatory-Certified Expansion	Macuject achieves FDA clearance for its web app, enabling a formal commercial rollout in the United States and adoption by large integrated delivery networks.	Successful completion of the FDA approval process for the platform, which the company has cited as a capital use [mivision 2022].	The team's CTO has led SOC2 and HIPAA compliance efforts, demonstrating a foundational focus on the regulatory requirements of the U.S. market [Bradley Beddoes LinkedIn].
Pharma Partnership & Embedded Use	The platform is adopted by pharmaceutical companies as a companion tool for clinical trials and therapy monitoring, creating a locked-in, high-value customer segment.	A partnership with a manufacturer of Optical Coherence Tomography (OCT) devices or a drug developer for wet AMD therapies.	The company explicitly lists pharma companies and OCT manufacturers as target customers, indicating a designed-in commercial strategy [Macuject.com].

Compounding for Macuject would manifest as a clinical data and workflow moat. Each new clinic using the platform generates more structured treatment data and refines the clinical decision trees. This creates a feedback loop where the software becomes more tailored to real-world practice, increasing its utility and stickiness for existing users while raising the barrier for new entrants. The platform's design for customization suggests this flywheel is built into the product from the start, allowing it to learn and adapt from diverse clinical settings [Macuject.com].

The size of the win can be framed by looking at the value of capturing a portion of the wet AMD treatment workflow. While a precise TAM is not publicly available, the commercial precedent is clear. Publicly traded digital health companies focused on specialty care workflows, such as Doximity for physician networks or Veeva for life sciences, trade at significant revenue multiples based on their entrenched user bases. A more direct, though earlier-stage, comparable could be the acquisition multiples for AI imaging analytics companies in adjacent fields like cardiology or neurology. If the "Regulatory-Certified Expansion" scenario plays out and Macuject secures a material footprint in U.S. clinics, its value could approach the hundreds of millions to low billions captured by successful vertical SaaS companies in healthcare (scenario, not a forecast). The underlying driver is the high lifetime value of a specialist physician user and the recurring revenue model inherent in a clinical SaaS platform.

Data Accuracy: YELLOW -- Opportunity framing is based on company-stated goals and early use evidence; specific market size and comparable valuation data are not independently confirmed.

Sources

PUBLIC

1. [PitchBook, 2025] Macuject 2025 Company Profile | https://pitchbook.com/profiles/company/520529-14

2. [Bionics Institute] From clinician to entrepreneur with Dr Devinder Chauhan - Bionics Institute | https://www.bionicsinstitute.org/podcasts-videos-media/from-clinician-to-entrepreneur-with-dr-devinder-chauhan/

3. [Macuject.com] Macuject | https://www.macuject.com/

4. [mivision, 2021] Paying it Forward: A Free AI Solution to Improve Outcomes for nAMD - mivision | https://mivision.com.au/2022/05/paying-it-forward-a-free-ai-solution-to-improve-outcomes-for-namd/

5. [Medium, Unknown] Why We Invested in Macuject. by Scarlett Chen | https://medium.com/verge-healthtech/why-we-invested-in-macuject-b9a937c150ed

6. [Macuject.com/blog-pages/andhealth-plus] Macuject Blog - ANDHealth+ | https://www.macuject.com/blog-pages/andhealth-plus

7. [Bradley Beddoes LinkedIn] Bradley Beddoes - Greater Brisbane Area | Professional Profile | LinkedIn | https://www.linkedin.com/in/bradleybeddoes/

8. [Crunchbase] Macuject Company Profile | https://www.crunchbase.com/organization/macuject

9. [Bounce Watch] Macuject - AI, Health Care Company Profile, Funding Rounds and Investors - Bounce Watch | https://bouncewatch.com/explore/startup/macuject

10. [HealthTechAlpha] Macuject | https://www.healthtechalpha.com/venture/macuject

11. [mivision, 2022] Paying it Forward: A Free AI Solution to Improve Outcomes for nAMD - mivision | https://mivision.com.au/2022/05/paying-it-forward-a-free-ai-solution-to-improve-outcomes-for-namd/

12. [CBInsights] Macuject CBInsights | https://www.cbinsights.com/company/macuject